LC
ABBV icon

Lincoln Capital’s AbbVie ABBV Stock Holding History

Lincoln Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$266K Sell
1,015
-32
-3% -$8.2K 0.05% 124
2026
Q2 		$263K Buy
1,047
+46
+5% +$9.9K 0.05% 124
2026
Q1 		$218K Hold
1,001
– – 0.04% 126
2025
Q4 		$229K Hold
1,001
– – 0.04% 122
2025
Q3 		$234K Buy
+1,001
New +$204K 0.04% 119
2019
Q1 		– Sell
-2,214
Closed -$204K – 73
2018
Q4 		$204K Buy
2,214
+10
+0.5% +$879 0.11% 67
2018
Q3 		$208K Buy
+2,204
New +$209K 0.1% 74

Other funds holding ABBV

HCM
Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Lincoln Capital's ABBV Position: Q3 2026 in Review

Lincoln Capital reduced its AbbVie (ABBV) stake by 3.1% in Q3 2026, selling an estimated $8.2K and leaving 1,015 shares worth $266K. The position accounts for 0.05% of the portfolio, ranked #124.

Lincoln Capital first reported a position in ABBV in Q3 2018 and has held it in 7 quarters since. 246 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Lincoln Capital held 1,015 shares of AbbVie worth $266K as of Q3 2026.
  • Lincoln Capital sold 32 AbbVie shares in Q3 2026, an estimated $8.2K.
  • AbbVie made up 0.05% of Lincoln Capital's portfolio in Q3 2026, its #124 holding.
  • Lincoln Capital first reported a position in AbbVie in Q3 2018 and has held it in 7 quarters since.
  • 246 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Lincoln Capital's 13F filing for Q3 2026, filed 9 Oct 2026.